Understanding how CNPY2 influences liver cancer progression through immune cells.
Official title: Defining the role of CNPY2 in promoting tumor progression through mediation of macrophage.
Funded at Ohio State University · NIH-11010788 · Data updated 2026-11-12
This study is looking at a protein called CNPY2 to see how it influences immune cells in liver cancer, which could help us understand more about how liver cancer grows and find better ways to treat it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | February 13, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $463,704 |
| NIH project number | 5R01CA270166-03 |
| Project ID | NIH-11010788 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with liver cancer or those at high risk for developing liver cancer.
✕Less likely to help
Patients with cancers unrelated to liver or those without any liver disease may not benefit from this research.
What this research studies
This research investigates the role of a protein called CNPY2 in liver cancer, particularly how it affects immune cells known as macrophages. By using genetic techniques, the study aims to uncover how CNPY2 contributes to inflammation and tumor growth in the liver. The researchers will explore the mechanisms by which CNPY2 regulates the production of specific inflammatory signals that can promote cancer. This work could lead to new insights into how liver cancer develops and how it might be treated.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that target CNPY2 to improve outcomes for liver cancer patients.
How similar studies have gone: Previous research has shown promising results in targeting immune pathways in cancer, suggesting that this approach could be effective.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Hong, Feng — Ohio State University
- Study coordinator: Hong, Feng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.